This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Tuesday's Health Winners & Losers

Health indices were boosted by an array of positive clinical trial news to start the holiday-shortened week Tuesday.

InterMune (ITMN) gained after announcing the Food and Drug Administration approved its amended clinical trial authorization (CTA) for ITMN-191, an orally available hepatitis C virus protease inhibitor that it's developing with Roche.

InterMune said in May that it would amend the CTA to take into consideration new information from a phase Ia study that was completed that month. The company expects to begin the phase Ib study this month and to announce initial top-line results in the first quarter of 2008.

The stock rose $2.06, or 10.4%, to $21.83, helping to support the Nasdaq biotechnology index, which added 16.4, or 2.4%, to 830.1.

Also winning Tuesday, NeurogesX (NGSX) announced positive top-line results from a phase III trial of NGX-4010, its dermal patch for patients with postherpetic neuralgia, or PHN, a neuropathic-pain condition. Shares climbed $1.16, or 16.3%, to $8.27.

In addition, Clinical Data (CLDA) announced positive results from a phase III study of antidepressant Vilazodone that also identified potential genetic markers for patient response to the drug. Shares rose 77 cents, or 3%, to $26.77.

Sciele Pharma (SCRX) said the FDA accepted its supplemental new-drug application for new dose formulations of hypertension treatment Sular for review with the goal-completion date of Nov. 2.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ITMN $73.89 -0.03%
NGSX $0.01 0.00%
LLY $73.58 0.00%
MRK $57.75 0.00%
AAPL $123.25 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs